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Counterpoint: Intensive Glucose Control
and Mortality in ACCORD—Still Looking for
Clues
E
arly cessation of the intensive glyce-
mic treatment arm of the Action to
Control Cardiovascular Risk in Dia-
betes (ACCORD) trial because of a 22%
excess of all-cause mortality compared
with the standard arm (1) came as an un-
pleasant surprise to many observers.
Sincethen,considerablediscussionofthe
signiﬁcance of this result has ensued
along with various theories as to why it
occurred. In the companion article, a re-
spected statistician, John Lachin, pro-
poses yet another hypothesis: that the
ﬁnding was due to the play of chance (2).
In response, this article will address three
related issues: 1) Dr. Lachin’s hypothesis;
2) a review of ﬁndings of post hoc analy-
ses of the ACCORD data seeking support
or lack of support for the other main the-
ories; and 3) my own opinions on why
continued study of the ACCORD data are
needed, including a reformulation of one
of the original theories regarding the
cause of excess mortality.
The play-of-chance hypothesis
“How often have I said to you that when
you have eliminated the impossible,
whatever remains, however improbable,
must be the truth?” asked Sherlock
Holmes of Dr. Watson in The Sign of the
Four (1890).
Dr. Lachin’s exposition of the theory
that the apparent excess of mortality in
ACCORDwasduetotheplayofchanceis
very welcome. This possibility has not
previously been given enough attention.
The excess of deaths with the intensive
glycemic treatment strategy was indeed
notlarge,a22%relativeincreasefrom1.1
to 1.4% of participants affected per year
(1). In absolute terms, it was 257 versus
203 deaths or an excess of 54 among
10,251 study participants. Had this been
the primary end point, a direct compari-
son would have shown the level of statis-
tical signiﬁcance generally regarded as
conclusive.Butitwasnottheprimaryend
point and repeated measurements were
made, increasing the likelihood of draw-
ing an erroneous conclusion. However,
thisproposalcannotbeevaluatedwithout
context. The quotation above from Sher-
lock Holmes (alter ego of the author Dr.
Arthur Conan Doyle) describes this di-
lemma. If other explanations are proven
extremely unlikely, then the play-of-
chance hypothesis looks good. The main
hypotheses to explain excess mortality
with intensive glycemic treatment in
ACCORD have concerned: 1) an overly
rapid reduction and maintenance of low
A1C levels; 2) effects of severe hypoglyce-
mia; 3) high doses of potentially harmful
individual drugs or drug combinations;
or 4) weight gain with its own harmful
consequences. Because we have not elim-
inated some of these plausible mecha-
nisms, it seems premature to put play-of-
chance at the top of the list. But surely it
belongs on the list, so we’ll add: 5) a play
of chance.
Considering the above, is there rea-
son to think the Data and Safety Monitor-
ingBoard(DSMB)wasinerrorinadvising
that intensive glycemic treatment be
halted? I think clearly not. The DSMB’s
charge was to protect the participants’
collective safety by reviewing data cur-
rently available, identifying trends, and
assessingfuturepossibilities.Itsmembers
had no way to know whether or not a
speciﬁc cause for excess mortality would
befound,andnostatisticalformulacould
perform the task required. As Dr. Lachin
correctly points out, their recommenda-
tion to halt the study on the basis of the
information then available cannot be
criticized.
What we have learned so far from
post hoc analyses in ACCORD
“I have devised seven separate explana-
tions,eachofwhichwouldcoverthefacts
as far as we know them. But which of
theseiscorrectcanonlybedeterminedby
the fresh information which we shall no
doubt ﬁnd waiting for us,” said Sherlock
Holmes to Dr. Watson in The Adventure of
the Copper Beeches (1892).
Of the four original hypotheses re-
garding causes of excess mortality, two
have not yet been adequately studied.
These are the potential effects of speciﬁc
drugs or drug combinations and the ef-
fects of weight gain. The hypothesis that
hasbeenmosthelpfullyaddressedbypost
hoc analyses is that rapid reduction and
maintenanceoflowA1Clevelswasharm-
ful.TherationaleforACCORDcamefrom
prior epidemiologic ﬁndings that greater
degrees of hyperglycemia in type 2 diabe-
tes subjects, reﬂected by higher A1C,
correlatedwithhigherriskofbothcardio-
vascular death and nonfatal cardiovascu-
lar events (3). Epidemiologic analysis of
data from the truncated period of ran-
domized treatment has conﬁrmed this re-
lationship (4). This presents a paradox:
higher A1C is associated with higher risk,
yet a treatment strategy that maintained
median A1C at 6.4% led to higher risk
compared with one keeping median A1C
at7.5%.Theparadoxispartlyresolvedby
thefurtherﬁndingthattheintensivestrat-
egy signiﬁcantly changed the relationship
between A1C and risk of death (interac-
tion P  0.0007). The association of
higher A1C with higher risk was stronger
with the intensive strategy (hazard ratio
for 1% higher updated average A1C 1.66,
P  0.0001) than with the standard strat-
egy (1.14, P  0.17) (4). The participants
seeking near-normal glycemic control
who had average A1C below 7% were not
the ones with increased risk, but rather it
was those with higher values. Further
analyses showed that individuals who
failed to reduce A1C from baseline val-
ueswhenattemptingtheintensivestrat-
egy seemed at greater risk (4). These
ﬁndings reject the rapid-A1C-reduction
hypothesis.
Examination of the association be-
tween severe hypoglycemia and mortality
has not supported the view that hypogly-
cemia is a likely mediator of harm with
intensive treatment (5,6). Severe hypo-
glycemiawasinfrequentlyassociatedwith
death in either arm in ACCORD. Having
had a severe hypoglycemic event did
increase risk of later death with both
intensive and standard treatments, but
participants using the intensive strategy
who had at least one severe event were
less likely to die at a later time than those
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perienced a severe event. This observa-
tion fails to conﬁrm the hypoglycemia
hypothesis but may not exclude it
entirely.
Why keep trying to ﬁnd a cause?
If the 22% increased risk of death accom-
panying the intensive treatment strategy
is potentially due to chance alone, why
continue looking for other possible
causes? A short answer to the question is
that there are other plausible explana-
tions. A longer answer must include the
entirerationaleforperformingclinicaltri-
als. A well designed trial is intended to
answer one primary question but can
further contribute by posing additional
hypotheses. In the case of the UK Pro-
spective Diabetes Study (UKPDS), the
question was whether intensiﬁed treat-
ment with single-agent pharmacotherapy
shortly after diagnosis of type 2 diabetes
would reduce microvascular or cardio-
vascularcomplicationsofthedisease.The
randomized treatment period conﬁrmed
microvascular but not cardiovascular
beneﬁt (7). However, other analyses
made major contributions: deﬁning the
progressive course of type 2 diabetes (8),
conﬁrming longer-term cardiovascular
beneﬁt (9), demonstrating persistence of
microvascular beneﬁt long after cessa-
tion of intensiﬁed treatment (the legacy
effect) (9), and suggesting unique car-
dio-protective effects of metformin
(10). These insights were the products of
secondary, post hoc, or epidemiologic
analyses, but they have guided subse-
quent studies and clinical decisions. In
thecaseofACCORD,allthreepartsofthe
trial (glucose, blood pressure, and lipid
interventions) tested whether very inten-
sive regimens could limit rates of cardio-
vascular events more than standard
therapies in a population of patients with
high cardiovascular risk and long-
duration type 2 diabetes. None of the in-
tensive interventions had a signiﬁcant
effect on the primary end point, a com-
posite of all-cause mortality, nonfatal
myocardial infarction, and nonfatal
stroke (2,11,12). One logical interpreta-
tion of these ﬁndings is that established
cardiovascular disease in diabetes is not
easily reversed. In this way overt cardio-
vascular disease may be similar to estab-
lisheddiabeticnephropathy,theeffectsof
which can be mitigated by various means
buttheconditionitselfcannotbereversed
by treatment of hyperglycemia or hyper-
tension.However,likeUKPDS,ACCORD
is likely to advance our understanding
and treatment of type 2 diabetes in other
ways. For example, drawing on the in-
sights of both UKPDS and ACCORD (and
also the Diabetes Control and Complica-
tions Trial [DCCT]), we now have reason
to ask whether very early intervention in
type 2 diabetes can establish a positive
legacy effect by preventing the earliest in-
jury to tissue by glycation or oxidative
stress, thereby delaying or minimizing
later cardiovascular risks that may prove
irreversible.
In the shorter term, two additional
hypotheses may be reﬁned by further
analyses of data from ACCORD. The ﬁrst
concerns the apparently vulnerable sub-
group of patients who, when attempting
the intensive glycemic treatment strategy,
were unable to reduce A1C and maintain
it below 7%. Deﬁning that subgroup and
identifying what features contributed to
higherriskofdeathwouldbeasigniﬁcant
contribution, perhaps leading to new tac-
tics in managing type 2 diabetes. If differ-
ent therapeutic targets are appropriate for
different groups of patients, ﬁnding ways
to assign individuals to the right category
wouldalsopermitnewformsoftreatment
to be tested.
A second hypothesis concerns the
role of hypoglycemia, which cannot be
entirely dismissed as a contributor to risk
in such patients. Beside the main obser-
vations regarding severe hypoglycemia
reviewed above, there were other notable
ﬁndings. The risk of severe hypoglycemic
events was epidemiologically associated
with higher rather than lower A1C values
in both arms of the study (6). This sur-
prisingpatternhasbeenreportedinother
studies (13,14) and draws further atten-
tion to those individuals attempting in-
tensive treatment whose A1C levels
remained above 7% and who appeared at
greater risk of death. Also, study of re-
ports of nonsevere hypoglycemia from a
subset of participants who also reported
at least one severe hypoglycemic event
suggested that prior minor hypoglycemia
might be protective against later death
(5). A potential mechanism for such an
effect is known. Repeated mild or moder-
ate hypoglycemia can suppress the usual
responseofcatecholamines,whichcauses
the most apparent symptoms of hypogly-
cemiaandalsocontributestothereturnof
plasma glucose toward normal levels
(15). Usually this syndrome of “hypogly-
cemia unawareness” is considered harm-
ful in predisposing to severe events that
can lead to automobile accidents or other
serious injuries. However, blunting of
catecholamine responses may have a pro-
tectiveeffectaswellbylimitingtheriskof
potentially fatal arrhythmias during a
later more serious hypoglycemic event.
Minor hypoglycemia was very common
during intensive glycemic treatment in
ACCORD. Is it possible that isolated se-
verehypoglycemia,notprecededbymi-
nor hypoglycemia, could be a mediator
of excess mortality in the individuals
attempting intensive treatment but
continuingtohaveelevatedA1C?Thehy-
poglycemia hypothesis for excess mortal-
ity in ACCORD may need to be modiﬁed
to include the phenomenon of “hypogly-
cemic preconditioning.” Clariﬁcation of
suchphysiologicmechanismsmayleadto
improved tactics, in addition to graded
targets, for the treatment of high risk in-
dividuals with type 2 diabetes.
In summary, the possibility that the
excess mortality accompanying intensive
glycemic treatment in ACCORD was due
to chance cannot be excluded. However,
other candidate mechanisms have not yet
been convincingly excluded either. Fur-
ther study of the large and excellent data-
base from ACCORD may provide further
clues on this point and, more generally, is
likely to guide important changes in the
therapy of type 2 diabetes. Among these
areearlierinterventiontoprecludecumu-
lative tissue damage from hyperglycemia,
identiﬁcation of lower versus higher risk
subgroups that require speciﬁc glycemic
treatmenttargetsandtactics,andperhaps
abroaderunderstandingoftheroleofhy-
poglycemia in cardiovascular risk.
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